In order to assess the impact of CCR6 on the later stages of cancerogenesis, MMTV-PyMT Ccr6WTand Ccr6−/− mice were sacrificed at 22–24 weeks of age and the total number of mammary tumors per mouse was determined. This evidence concerns the gene CCR6 and breast cancer.